Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Viral infections

Phase I trial of GlaxoSmithKline’s Ebola vaccine shows it is well tolerated

Phase 1 of the clinical trials of the chimpanzee adenovirus type 3–vectored ebola virus vaccine (cAd3-EBO), developed by GlaxoSmithKline (GSK) shows promising results

Source: Paul Doyle / Alamy

In a phase 1 clinical trial of the chimpanzee adenovirus type 3–vectored ebola virus vaccine, developed by GlaxoSmithKline, no major adverse events were reported

The 2014 outbreak of Ebola virus disease has sparked international efforts to develop a vaccine. One candidate being developed by GlaxoSmithKline (GSK) is a replication-defective recombinant chimpanzee adenovirus type 3–vectored ebolavirus vaccine (cAd3-EBO). It is bivalent, offering protection against the Zaire and Sudan strains, and has already demonstrated activity in a nonhuman primate model.

Now, preliminary results from a Phase I study published in The New England Journal of Medicine (online, 26 November 2014)[1] involving 20 healthy adults indicate that the vaccine is both immunogenic and safe. Immune responses to a single dose of vaccine were dose-dependent and there were no major adverse events, although two participants given the higher dose developed transient fever.

Clinical trials of cAd3-EBO are ongoing. GSK says it could produce one million doses a month by the end of 2015. 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20067285

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.